EW News and Press, Edwards Lifesciences Corporation From 08/11/20

This article is part of a series that provides an ongoing analysis of the changes made to Kenneth Fisher’s 13F stock portfolio on a quarterly basis. It is based on Fisher Asset Management’s regulatory 13F Form filed on 08/07/2020. Please visit our Tracking Kenneth Fisher's Fis...

Edwards Life Sciences (NYSE: EW ) has shown resilience amidst the recent market uncertainty, with a surprisingly sturdy Q2 exit showcased on July 23rd 2020 with clear guidance moving into the end of FY2020 and 2021. Whilst also beating Revenue and EPS estimates by $133.29 million and $0.10, re...

Edwards Lifesciences ( EW ) has been a growth star in the med-tech space for a while now, and with good reason, as the company’s leading transcatheter aortic valve replacement (or TAVR) offerings have driven double-digit growth for more than a decade, even with some bumps along the wa...

Investment Thesis We are extremely bullish on Thermo Fisher Scientific (TMO) and believe that the company has the fundamental momentum coupled with the economic pillars to provide shareholders excellent total returns in the coming periods. Currently, the market views TMO as one of the most...

Investors might not be overly excited about Edwards Lifesciences' (NYSE: EW) stock performance so far in 2020. But its shares are still beating the S&P 500 index. And the medical device maker now has a positive catalyst. Edwards Lifesciences announced its second-quarter results after ...

Edwards Lifesciences Corp. (EW) Q2 2020 Earnings Conference Call July 23, 2020 5:00 PM ET Company Participants Mark Wilterding – Vice President-Investor Relations Mike Mussallem – Chairman and Chief Executive Officer Scott Ullem – Chief Financial Officer C...

Edward Lifesciences (NYSE: EW ) Q2 results : More news on: Edwards Lifesciences Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Edwards Lifesciences (NYSE: EW ) : Q2 Non-GAAP EPS of $0.34 beats by $0.15 ; GAAP EPS of -$0.20 beats by $0.10 . Revenue of $925M (-15.1% Y/Y) beats by $133.29M . FY20 adjusted EPS guidance increased: $1.75-$1.95 from $1.58-$1.75 earlier. Press Release More news on: Edwards Lif...

While I thought Abbott Labs ( ABT ) was relatively well-placed relative to its peers through the Covid-19 pandemic with my last update , I also thought that the valuation was pretty full overall. Since then, the shares have done a little better than peers like Becton Dickinson ( BDX ), ...

IRVINE, Calif. , July 15, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Paul A. LaViolette has been appointed to its board of directo...